RVL Pharmaceuticals plc (NASDAQ:RVLP) Q4 2022 Earnings Call Transcript

Page 7 of 7

What we want to do is operate as efficiently as possible, drive leverage off the P&L, and we’re doing it right now, and bring in programs that could help absorb our basic model right now with additional revenue streams. Again, there’s a lot of those conversations ongoing right now, so guidance for me at this point would be premature.

Jeff Santangelo: Okay, thanks for the thoughts.

Brian Markison: Thank you.

Operator: It appears that we have no further questions at this time. I will now turn the program back over to Brian Markison for any additional or closing remarks.

Brian Markison: Thanks Operator, and thanks everyone for listening into our call today. I think it’s really important to keep front and center the fact that we are a unique product in the marketplace. We do not compete in the traditional esthetic markets of fillers and toxins. We are a very simple product to administer and we make everybody look better who gets it, literally within minutes after they’ve received a sample. We’re excited about our product, we love the growth we’re seeing, and I want to thank again everyone for sticking with us and listening to the call today. Thanks Operator.

Operator: That concludes today’s teleconference. Thank you for your participation. You may now disconnect.

Follow Rvl Pharmaceuticals Plc

Page 7 of 7